AAM Strengthens Calls For Reforms To Stop Anticompetitive Tactics
Six Areas Listed Including Skinny Label Carve Outs
The US Association for Accessible Medicines discussed six areas for reform during a recent US Senate Judiciary Committee hearing “shining a spotlight on the anti-competitive tactics used by some brand name pharmaceutical companies to delay patient access” to generics and biosimilars.
You may also be interested in...
In a suit closely watched by industry, a US district magistrate judge found that Amarin had at least stated a plausible claim in its case accusing Hikma and US healthcare insurance provider Health Net of induced infringement of Vascepa method-of-use patents, which Hikma has carved out of its generic label.
AbbVie delayed biosimilar competition to Humira “for far longer than warranted” and may have “engaged in other anti-competitive conduct to maintain its market share and pricing power” for the adalimumab brand, according to members of the US House of Representatives’ committee on oversight and reform. The US Federal Trade Commission has been urged to open a formal inquiry into the originator’s conduct.
Proposed state legislation restricting patent settlements set out in Oregon’s SB 764 bill is “unnecessary,” the AAM has insisted, opposing the “unconstitutional” legislation by citing delayed patient access to affordable medicines, the obstruction of expedited patent settlements and benefits to brand-name pharmaceutical companies which will eventually lead to price rises.